H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on Vir Biotechnology to $100 from $125 and keeps a Buy rating on the shares following the Q4 results. The company has a "chock-full of datasets" and potential to separate from a crowded HBV field as the story moves beyond COVID-19, the analyst tells investors in a research note. The firm says the Phase 2 trial combining VIR-2218 plus interferon is demonstrating robust results so far.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VIR:
- 3 Stocks to Buy Today, 3/6/2023, According to Top Analysts
- Vir Biotechnology upgraded to Overweight from Neutral at JPMorgan
- Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
- Vir Biotechnology reports Q4 EPS (76c), consensus (39c)
- Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results